MULTIPLE INDICATION PRICING, REIMBURSEMENT AND FUNDING DYNAMICS: THE CASE OF ORPHAN INDICATIONS

被引：0
|
作者：
Wild, L. [1 ]
Forster, L. [1 ]
机构：
[1] Double Helix Consulting, London, England
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.566
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A335 / A336
页数：2
相关论文
共 50 条
  • [31] HOW CAN PHARMA INDUSTRY PREPARE ITSELF FOR THE CHANGING PRICING AND REIMBURSEMENT LANDSCAPE OF ORPHAN DRUGS IN EU?
    Mukku, S.
    Pang, F.
    Mcconkey, D.
    VALUE IN HEALTH, 2011, 14 (07) : A357 - A357
  • [32] MARKET ACCESS, PRICING AND REIMBURSEMENT PROCESSES FOR ORPHAN DRUGS IN THE EU-5 COUNTRIES: A COMPARATIVE ASSESSMENT
    Vollmer, L.
    Prada, M.
    Benazet, F.
    Berard, I
    Lopez, N.
    Guterres, S.
    Walzer, S.
    VALUE IN HEALTH, 2019, 22 : S854 - S854
  • [33] Pricing and reimbursement policy for new orphan drugs in South Korea: focused on patient accessibility and budget impact
    Lee, Jong Hyuk
    Yoo, Seung-Lai
    EXPERT OPINION ON ORPHAN DRUGS, 2022, 10 (01): : 23 - 28
  • [34] CAN PRICE-PREVALENCE TRENDS BE USED TO GUIDE THE PRICING AND REIMBURSEMENT STRATEGY FOR NEW ORPHAN DRUGS? A TWO-COUNTRY CASE STUDY
    Vanoni, C.
    Laughlin, W.
    Rakonczai, P.
    Katsoulis, I. A.
    Bending, M. W.
    VALUE IN HEALTH, 2020, 23 : S610 - S610
  • [35] Correction: From Indication-Based Pricing to Blended Approach: Evidence on the Price and Reimbursement Negotiation in Italy
    Elvio Emanuele Rossini
    Carlotta Galeone
    Chiara Lucchetti
    Claudio Jommi
    PharmacoEconomics - Open, 2024, 8 (2) : 345 - 345
  • [36] IMPLICATIONS OF INDICATION EXPANSIONS ON PRICING AND REIMBURSEMENT AND HOW THIS DIFFERS BETWEEN EU4 AND UK MARKETS
    Baig, M.
    Nicol, G.
    Vadehra, R.
    Craddy, P.
    VALUE IN HEALTH, 2024, 27 (12) : S379 - S379
  • [37] IS THERE NO OPTIMAL APPROACH FOR ORPHAN DRUGS TO PATIENT ACCESS? RARE DISEASE IS NOT RARE AND NEEDS TO DEVELOP THE NEW PRICING AND REIMBURSEMENT SOLUTION
    Kim, S.
    Cho, Y.
    Shim, S.
    Lee, J.
    Kim, W.
    Bae, K.
    VALUE IN HEALTH, 2011, 14 (07) : A354 - A355
  • [38] The national drug formulary listing process for orphan drugs in South Korea: narrative review focused on pricing and reimbursement pathways
    Bang, Joon Seok
    Lee, Jong Hyuk
    EXPERT OPINION ON ORPHAN DRUGS, 2021, 9 (04): : 105 - 112
  • [39] Application of four pricing models for orphan medicines: a case study for lumasiran
    Rosenberg, Noa
    Manders, Evert
    van den Berg, Sibren
    Deesker, Lisa J.
    Garrelfs, Sander F.
    de Visser, Saco J.
    Groothoff, Jaap W.
    Hollak, Carla E. M.
    ORPHANET JOURNAL OF RARE DISEASES, 2024, 19 (01)
  • [40] CHALLENGES OF PRICING STRATEGY FOR DRUGS BEING LAUNCHED IN MULTIPLE ONCOLOGY INDICATIONS
    Edathodu, A.
    Gonzalez, A. O.
    Leung, S. K.
    Mukku, S. R.
    VALUE IN HEALTH, 2017, 20 (05) : A132 - A133
12345